All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

carbocisteine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
mucolytics	4160	638-23-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: carbocisteine bronchokod carbocit carbocysteine chilvax L-(Carboxymethyl)cysteine lisil lisomucil loviscol muciclar mucocis mucodyne mucofan mucolase mucolex mucopront mucosol mucotab mukinyl PectDrill pectox pulmoclase reomucil rhinathiol rhinatiol thiodril transbronchin carbocisteine sodium	A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action. Molecular weight: 179.19 Formula: C5H9NO4S CLOGP: -2.61 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 100.62 ALOGS: -0.92 ROTB: 5

Drug dosage:

Dose	Unit	Route
1.50	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary pain	106.20	18.47	32	7842	3458	63477690
Upper respiratory tract inflammation	80.51	18.47	24	7850	2499	63478649
Hepatic function abnormal	73.97	18.47	50	7824	37092	63444056
Amyloid arthropathy	70.56	18.47	16	7858	564	63480584
Drug ineffective	67.54	18.47	23	7851	1044742	62436406
Interstitial lung disease	63.10	18.47	56	7818	61852	63419296
Drug eruption	55.63	18.47	38	7836	28656	63452492
Lower respiratory tract infection	55.60	18.47	75	7799	132232	63348916
Platelet count decreased	53.70	18.47	69	7805	116053	63365095
Adrenal suppression	53.40	18.47	14	7860	910	63480238
Pneumonia bacterial	49.63	18.47	24	7850	9441	63471707
Pain	41.70	18.47	20	7854	740608	62740540
Pneumonia	41.05	18.47	137	7737	456630	63024518
Adjusted calcium decreased	38.65	18.47	8	7866	182	63480966
Fatigue	37.75	18.47	33	7841	887995	62593153
Asthma	37.28	18.47	61	7813	127500	63353648
Drug-induced liver injury	34.39	18.47	33	7841	40189	63440959
Infective exacerbation of bronchiectasis	33.71	18.47	8	7866	345	63480803
Asteatosis	33.69	18.47	6	7868	59	63481089
Cardiac failure	33.62	18.47	48	7826	89094	63392054
Haemoptysis	33.33	18.47	28	7846	28698	63452450
Pyrexia	32.82	18.47	130	7744	470348	63010800
Hyponatraemia	32.00	18.47	53	7821	111847	63369301
Upper gastrointestinal haemorrhage	31.95	18.47	23	7851	18829	63462319
Diarrhoea	31.71	18.47	173	7701	715193	62765955
Blood prolactin increased	31.63	18.47	13	7861	3490	63477658
Pneumonia aspiration	28.89	18.47	28	7846	34512	63446636
Palpitations	26.50	18.47	49	7825	112721	63368427
Stevens-Johnson syndrome	26.26	18.47	23	7851	24927	63456221
Lip swelling	25.64	18.47	25	7849	31038	63450110
Myopathy	24.52	18.47	16	7858	11175	63469973
Reversible cerebral vasoconstriction syndrome	24.46	18.47	10	7864	2648	63478500
Erythema multiforme	23.41	18.47	15	7859	10154	63470994
Galactorrhoea	23.19	18.47	11	7863	4144	63477004
Gastroenteritis	23.07	18.47	22	7852	26568	63454580
Hypoglycaemia	22.13	18.47	32	7842	60033	63421115
Pharyngitis	22.06	18.47	19	7855	20124	63461024
Joint swelling	21.40	18.47	7	7867	327659	63153489
Drug interaction	20.73	18.47	69	7805	229062	63252086
Constipation	20.59	18.47	68	7806	224875	63256273
Tendonitis	20.47	18.47	18	7856	19597	63461551
Sputum retention	20.40	18.47	6	7868	596	63480552
Enteritis infectious	19.58	18.47	8	7866	2116	63479032
Urine output decreased	19.56	18.47	14	7860	11356	63469792
Obesity	19.11	18.47	21	7853	29931	63451217
Pneumomediastinum	18.88	18.47	7	7867	1429	63479719

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	152.40	16.96	126	8314	65156	34883335
Hepatic function abnormal	102.11	16.96	85	8355	44278	34904213
Pneumonia aspiration	85.61	16.96	75	8365	41828	34906663
Pneumonia	81.90	16.96	231	8209	362396	34586095
Lower respiratory tract infection	79.87	16.96	64	8376	31573	34916918
Radiation inflammation	70.58	16.96	20	8420	885	34947606
Pulmonary pain	64.61	16.96	20	8420	1204	34947287
Idiopathic pulmonary fibrosis	47.15	16.96	21	8419	3513	34944978
Lung neoplasm malignant	41.36	16.96	34	8406	17361	34931130
Drug ineffective	39.05	16.96	32	8408	456719	34491772
Upper respiratory tract inflammation	39.03	16.96	15	8425	1729	34946762
Fatigue	38.33	16.96	21	8419	370632	34577859
Pneumonia bacterial	36.46	16.96	27	8413	11845	34936646
Malignant neoplasm progression	33.63	16.96	69	8371	87977	34860514
Liver disorder	32.57	16.96	40	8400	32957	34915534
Drug eruption	29.79	16.96	30	8410	19868	34928623
Paraneoplastic rash	27.49	16.96	6	8434	88	34948403
Antibody test abnormal	27.29	16.96	7	8433	211	34948280
Schizophrenia	27.26	16.96	20	8420	8646	34939845
Neutrophil count decreased	26.94	16.96	46	8394	51058	34897433
Clumsiness	25.39	16.96	11	8429	1721	34946770
Drug-induced liver injury	25.36	16.96	33	8407	28799	34919692
Somnambulism	22.15	16.96	12	8428	3060	34945431
Condition aggravated	21.83	16.96	98	8342	192098	34756393
Mouth swelling	21.51	16.96	10	8430	1846	34946645
Knee arthroplasty	20.79	16.96	16	8424	7428	34941063
Gastric mucosal lesion	20.47	16.96	7	8433	578	34947913
Dyspnoea	20.47	16.96	158	8282	376624	34571867
Hypophagia	20.35	16.96	27	8413	23995	34924496
Eye infection	20.16	16.96	12	8428	3661	34944830
Toxicity to various agents	19.73	16.96	12	8428	200350	34748141
Clonic convulsion	19.70	16.96	7	8433	647	34947844
Duodenal ulcer perforation	19.56	16.96	9	8431	1623	34946868
Inappropriate antidiuretic hormone secretion	18.67	16.96	19	8421	12734	34935757
Pneumothorax	18.60	16.96	23	8417	19069	34929422
Radiation pneumonitis	18.17	16.96	10	8430	2630	34945861
Genital pain	17.82	16.96	6	8434	472	34948019

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	199.58	15.57	174	16355	112426	79615433
Hepatic function abnormal	171.47	15.57	133	16396	72974	79654885
Pulmonary pain	158.41	15.57	52	16477	4421	79723438
Pneumonia	118.82	15.57	352	16177	659894	79067965
Upper respiratory tract inflammation	111.73	15.57	39	16490	3996	79723863
Pneumonia aspiration	105.68	15.57	97	16432	66870	79660989
Drug ineffective	95.54	15.57	53	16476	1080860	78646999
Lower respiratory tract infection	85.51	15.57	119	16410	129101	79598758
Pneumonia bacterial	77.76	15.57	49	16480	19282	79708577
Drug eruption	73.93	15.57	66	16463	43869	79683990
Radiation inflammation	73.59	15.57	20	16509	885	79726974
Fatigue	73.20	15.57	52	16477	929675	78798184
Amyloid arthropathy	62.38	15.57	16	16513	564	79727295
Platelet count decreased	61.52	15.57	129	16400	194535	79533324
Drug-induced liver injury	51.54	15.57	66	16463	66051	79661808
Idiopathic pulmonary fibrosis	49.80	15.57	22	16507	4206	79723653
Pain	48.27	15.57	45	16484	703757	79024102
Malignant neoplasm progression	45.14	15.57	92	16437	135898	79591961
Hyponatraemia	45.11	15.57	108	16421	177740	79550119
Haemoptysis	42.23	15.57	55	16474	55944	79671915
Upper gastrointestinal haemorrhage	41.57	15.57	47	16482	41333	79686526
Cardiac failure	41.40	15.57	96	16433	154746	79573113
Pyrexia	39.57	15.57	258	16271	678451	79049408
Completed suicide	39.52	15.57	3	16526	245764	79482095
Liver disorder	38.21	15.57	60	16469	72357	79655502
Adrenal suppression	36.73	15.57	13	16516	1386	79726473
Toxicity to various agents	36.57	15.57	21	16508	421519	79306340
Neutrophil count decreased	35.33	15.57	67	16462	93892	79633967
Asthma	35.28	15.57	83	16446	135012	79592847
Stevens-Johnson syndrome	35.18	15.57	42	16487	39124	79688735
Drug hypersensitivity	33.80	15.57	10	16519	298906	79428953
Febrile convulsion	33.50	15.57	11	16518	935	79726924
Pneumothorax	33.39	15.57	35	16494	28288	79699571
Adjusted calcium decreased	33.21	15.57	8	16521	217	79727642
Lung neoplasm malignant	32.15	15.57	34	16495	27758	79700101
Dyspnoea	29.67	15.57	289	16240	856736	78871123
Asthenia	29.20	15.57	38	16491	511651	79216208
Tendonitis	29.08	15.57	30	16499	23800	79704059
Knee arthroplasty	28.82	15.57	40	16489	43208	79684651
Erythema multiforme	28.66	15.57	26	16503	17625	79710234
Paraneoplastic rash	28.40	15.57	6	16523	88	79727771
Constipation	28.35	15.57	125	16404	282925	79444934
Infective exacerbation of chronic obstructive airways disease	28.07	15.57	13	16516	2771	79725088
Sputum retention	28.07	15.57	10	16519	1087	79726772
Pneumomediastinum	27.55	15.57	14	16515	3653	79724206
Lip swelling	27.50	15.57	38	16491	40873	79686986
Asteatosis	27.46	15.57	6	16523	104	79727755
Infusion related reaction	27.34	15.57	7	16522	230230	79497629
Sputum increased	27.26	15.57	15	16514	4598	79723261
Hyperuricaemia	26.61	15.57	21	16508	11778	79716081
Orthostatic hypotension	26.18	15.57	44	16485	56120	79671739
Diarrhoea	25.31	15.57	286	16243	880203	78847656
Weight increased	25.23	15.57	13	16516	277373	79450486
Pharyngitis	25.22	15.57	27	16502	22348	79705511
Disseminated intravascular coagulation	25.16	15.57	34	16495	35808	79692051
Enterocolitis	24.79	15.57	22	16507	14490	79713369
Lymphangiosis carcinomatosa	24.70	15.57	11	16518	2143	79725716
Cerebral infarction	24.30	15.57	38	16491	45638	79682221
Altered state of consciousness	24.07	15.57	37	16492	43785	79684074
Weight decreased	23.94	15.57	23	16506	355175	79372684
Radiation pneumonitis	23.82	15.57	13	16516	3920	79723939
Nephrotic syndrome	23.31	15.57	19	16510	11155	79716704
Malaise	22.52	15.57	176	16353	489693	79238166
Gastric mucosal lesion	21.81	15.57	8	16521	945	79726914
Schizophrenia	21.72	15.57	21	16508	15419	79712440
Paraesthesia	21.63	15.57	5	16524	176318	79551541
Joint swelling	21.49	15.57	17	16512	288629	79439230
Therapeutic product effect decreased	21.44	15.57	4	16525	163859	79564000
Arthralgia	21.42	15.57	55	16474	571748	79156111
Fixed eruption	21.39	15.57	11	16518	2943	79724916
Blood prolactin increased	20.87	15.57	12	16517	3999	79723860
Bronchitis	20.83	15.57	67	16462	130577	79597282
Clumsiness	20.80	15.57	11	16518	3116	79724743
Chronic obstructive pulmonary disease	20.70	15.57	51	16478	85368	79642491
Antibody test abnormal	20.52	15.57	7	16522	669	79727190
Hypophagia	20.42	15.57	35	16494	45332	79682527
Rheumatoid arthritis	20.13	15.57	9	16520	208461	79519398
Enteritis infectious	20.12	15.57	11	16518	3327	79724532
Zinc deficiency	19.64	15.57	5	16524	171	79727688
Clonic convulsion	19.63	15.57	8	16521	1254	79726605
Melaena	18.78	15.57	40	16489	60850	79667009
Treatment failure	18.72	15.57	6	16523	170480	79557379
Pneumothorax spontaneous	18.53	15.57	8	16521	1446	79726413
Palpitations	18.46	15.57	63	16466	126547	79601312
Duodenal perforation	18.41	15.57	9	16520	2163	79725696
Fulminant type 1 diabetes mellitus	18.38	15.57	8	16521	1475	79726384
Reversible cerebral vasoconstriction syndrome	18.23	15.57	10	16519	3047	79724812
Non-small cell lung cancer	18.08	15.57	13	16516	6347	79721512
Myositis	17.95	15.57	21	16508	19147	79708712
Laryngopharyngitis	17.77	15.57	4	16525	80	79727779
Productive cough	17.58	15.57	49	16480	88282	79639577
Pulmonary alveolar haemorrhage	16.90	15.57	16	16513	11441	79716418
Delirium	16.89	15.57	47	16482	84580	79643279
Respiratory failure	16.68	15.57	78	16451	180833	79547026
Galactorrhoea	16.59	15.57	10	16519	3636	79724223
Mouth swelling	16.36	15.57	12	16517	6039	79721820
Gastroenteritis	16.28	15.57	27	16502	34055	79693804
Abnormal behaviour	16.26	15.57	28	16501	36393	79691466
Infective exacerbation of bronchiectasis	15.89	15.57	6	16523	768	79727091
Genital pain	15.60	15.57	6	16523	808	79727051

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R05CB03	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D005100	Expectorants
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:77034	mucolytics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gastrointestinal ulcer	contraindication	40845000
Gastrointestinal hemorrhage	contraindication	74474003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.15	acidic
pKa2	2.79	acidic
pKa3	9.51	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
N0000170286	NUI
D06393	KEGG_DRUG
C0006992	UMLSCUI
CHEBI:16163	CHEBI
CAY	PDB_CHEM_ID
CCS	PDB_CHEM_ID
CHEMBL396416	ChEMBL_ID
DB04339	DRUGBANK_ID
193653	PUBCHEM_CID
2023	RXNORM
26469	MMSL
d05062	MMSL
003677	NDDF
395842001	SNOMEDCT_US
772923009	SNOMEDCT_US
D002233	MESH_DESCRIPTOR_UI
2884	INN_ID
740J2QX53R	UNII

Pharmaceutical products:

None